Arabic Arabic English English French French German German
dark

Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy

Astellas Pharma Inc. reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on September 1, passed away on September 9. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of DirectorsMs. Williams-Brinkley brings more than 35 years of executive leadership experience in healthcare to the Travere Board

Next Post

MOH Calls for Taking 2 Doses of COVID-19 Vaccine to Prevent Variants

Related Posts
Total
0
Share